All posts
Published
June 23, 2025

Ebook: 2023 Healthcare Trends in Emerging Markets A Look Ahead

The Speyside Healthcare team has published its 2023 outlook, analyzing key trends shaping high-growth and emerging markets post-pandemic. Our analysis focuses on the urgent need for impactful, locally-rooted partnerships to address challenges from affordability and prevention to regulatory harmonization and AI integration. This report provides the critical insights global healthcare companies need to build lasting value and secure market access.

The Speyside Healthcare team has published its 2023 outlook, analyzing key trends shaping high-growth and emerging markets post-pandemic. Our analysis focuses on the urgent need for impactful, locally-rooted partnerships to address challenges from affordability and prevention to regulatory harmonization and AI integration. This report provides the critical insights global healthcare companies need to build lasting value and secure market access.

After being hit the hardest by the pandemic, many emerging market stakeholders are now looking for  impactful, long-term partnerships with global healthcare companies that add real value to local populations. Those companies that step-up and structure meaningful partnerships will reap benefits over time in terms of reputation, relationships and market access. However, any such partnerships need to be rooted in a deep understanding of the local environment.

At Speyside Group we have analyzed the landscape for healthcare in emerging markets and identified some trends that will shape healthcare systems in the
near term. This report contains a brief analysis of the main trends and opportunities that 2023 will bring in the  following areas:

  • The challenge of healthcare  affordability amid increasing healthcare costs.
  • The shift towards prevention focused healthcare systems.
  • Market access in the context of  regulatory harmonization and reliance.
  • Impactful collaboration to contribute  to enhanced innovation capacity across the globe.
  • Lasting changes in healthcare dynamics and patients after the pandemic.
  • Integration of AI, technology, and data analysis for healthcare decisions.
  • Climate Change & Healthcare.

Download our ebook here: Speyside 2023 Emerging Markets Healthcare Outlook

Conclusion

In 2023, healthcare systems in emerging markets will be shaped by rising costs, a shift toward prevention, increased use of technology, and the need for meaningful partnerships. Companies that go beyond transactional relationships and invest in deep, locally informed collaborations will position themselves as strategic allies. Innovation, regulatory harmonization, and climate change response will be key to building more resilient and equitable healthcare systems in the near future.

Recent News

View All News
Healthcare

How do pharma companies engage healthcare policy in Latin America?

Speyside Group provides a strategic perspective on how pharmaceutical companies influence healthcare policy in Latin America, mapping the seven principal channels of engagement across the region's leading regulatory and reimbursement bodies. Drawing on CONITEC data, Brazil's Partnerships for Productive Development, and coalition-building work with groups such as ERCAL and ILAR, the analysis shows why evidence generation and multi-stakeholder consensus consistently outperform formal lobbying in this market.
Read post
APAC

Singapore Puts Energy at the Center

Speyside Group provides a strategic perspective on Singapore's renaming of the Ministry of Trade and Industry to the Ministry of Energy, Trade and Industry (METI), effective October 1, 2026. The analysis examines what this Cabinet-level elevation of energy policy means for data center and AI-infrastructure operators, cross-border power trading under the ASEAN Power Grid, and the institutional signals investors should track through 2027.
Read post
Healthcare

How Do Pharmaceutical Companies Engage Patient Advocacy Groups (PAGs) in Emerging Markets?

Speyside Group provides a strategic perspective on patient advocacy group engagement in emerging markets, examining how multinational pharmaceutical companies structure compliant, locally embedded partnerships across Latin America, Asia, and Africa. Drawing on cases from Brazil, India, and Ghana, the analysis outlines the funding caps, disclosure practices, and neutral-channel strategies that separate durable market access programs from reputational and regulatory risk.
Read post